Inhibitors of sodium–glucose cotransporter 2 (SGLT2) and dipeptidyl peptidase 4 (DPP4) are widely used in patients with type 2 diabetes to improve glycaemic control and reduce cardiovascular risks. Two recent clinical trials, CREDENCE and DELIGHT, demonstrate that these drugs can also slow down the progression of kidney disease in these patients.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Relationship between protein-energy wasting in adults with chronic hemodialysis and the response to treatment with erythropoietin
BMC Nephrology Open Access 14 August 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Perkovic, V. et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1811744 (2019).
Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).
Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).
Wiviott, S. D. et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 380, 347–357 (2019).
Brenner, B. M. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861–869 (2001).
Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851–860 (2001).
Pollock, C. et al. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 7, 429–441 (2019).
Heerspink, H. J. L. et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomized clinical trials. Lancet Diabetes Endocrinol. 7, 128–139 (2019).
Rosenstock, J. et al. Effect of linagliptin versus placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321, 69–79 (2019).
Lupsa, B. C. & Inzucchi, S. E. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia 61, 2118–2125 (2018).
Acknowledgements
The authors are supported by a grant from the University of Oxford to the institution for conducting the EMPA-KIDNEY trial in Germany (EMPA-KIDNEY is sponsored and funded by Boehringer Ingelheim).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.W. is a Steering Committee member of EMPA-REG OUTCOME, EMPEROR Studies and EMPA-KIDNEY (all sponsored by Boehringer Ingelheim). C.W. received honoraria for consulting and lecturing from Abbott, Akibia, Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Fresenius Medical Care, GlaxoSmithKline, Sanofi Genzyme, Lilly, MSD, Novartis, Pfizer, Reata, Shire-Takeda, Tricida and Vifor. S.B. is a Steering Committee member of EMPA-KIDNEY (sponsored by Boehringer Ingelheim) and received honoraria from Novartis for consulting.
Rights and permissions
About this article
Cite this article
Wanner, C., Brenner, S. CREDENCE and DELIGHT deliver on renal benefits. Nat Rev Nephrol 15, 459–460 (2019). https://doi.org/10.1038/s41581-019-0171-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-019-0171-2
